Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.
about
Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Twice-daily Trizivir versus Co ...... n: a formulation-switch trial.
@en
Twice-daily Trizivir versus Co ...... n: a formulation-switch trial.
@nl
type
label
Twice-daily Trizivir versus Co ...... n: a formulation-switch trial.
@en
Twice-daily Trizivir versus Co ...... n: a formulation-switch trial.
@nl
prefLabel
Twice-daily Trizivir versus Co ...... n: a formulation-switch trial.
@en
Twice-daily Trizivir versus Co ...... n: a formulation-switch trial.
@nl
P2093
P2860
P1433
P1476
Twice-daily Trizivir versus Co ...... n: a formulation-switch trial.
@en
P2093
Alfred E Burnside
Charles E Farthing
ESS40005 Study Team
Margaret A Fischl
Mark S Shaefer
Melanie A Thompson
Nicholaos C Bellos
Paul G Wannamaker
Teresa L Kauf
Vanessa C Williams
P2860
P304
P356
10.1592/PHCO.23.14.1432.31944
P407
P577
2003-11-01T00:00:00Z